These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 10708416)

  • 1. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.
    Huang CY; Butrapet S; Pierro DJ; Chang GJ; Hunt AR; Bhamarapravati N; Gubler DJ; Kinney RM
    J Virol; 2000 Apr; 74(7):3020-8. PubMed ID: 10708416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3.
    Butrapet S; Huang CY; Pierro DJ; Bhamarapravati N; Gubler DJ; Kinney RM
    J Virol; 2000 Apr; 74(7):3011-9. PubMed ID: 10708415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.
    Huang CY; Butrapet S; Tsuchiya KR; Bhamarapravati N; Gubler DJ; Kinney RM
    J Virol; 2003 Nov; 77(21):11436-47. PubMed ID: 14557629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53.
    Kinney RM; Butrapet S; Chang GJ; Tsuchiya KR; Roehrig JT; Bhamarapravati N; Gubler DJ
    Virology; 1997 Apr; 230(2):300-8. PubMed ID: 9143286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus.
    Huang CY; Silengo SJ; Whiteman MC; Kinney RM
    J Virol; 2005 Jun; 79(12):7300-10. PubMed ID: 15919884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
    Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
    Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. IV. Characterization of a vaccine candidate in fetal rhesus lung cells.
    Halstead SB; Eckels KH; Putvatana R; Larsen LK; Marchette NJ
    Am J Trop Med Hyg; 1984 Jul; 33(4):679-83. PubMed ID: 6476215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
    Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
    J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction.
    Johnson BW; Chambers TV; Crabtree MB; Guirakhoo F; Monath TP; Miller BR
    Am J Trop Med Hyg; 2004 Jan; 70(1):89-97. PubMed ID: 14971704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii.
    Halstead SB; Marchette NJ
    Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):5-11. PubMed ID: 14740949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice.
    Chen W; Kawano H; Men R; Clark D; Lai CJ
    J Virol; 1995 Aug; 69(8):5186-90. PubMed ID: 7609092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses.
    Caufour PS; Motta MC; Yamamura AM; Vazquez S; Ferreira II; Jabor AV; Bonaldo MC; Freire MS; Galler R
    Virus Res; 2001 Nov; 79(1-2):1-14. PubMed ID: 11551641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus.
    Chang GJ; Hunt AR; Holmes DA; Springfield T; Chiueh TS; Roehrig JT; Gubler DJ
    Virology; 2003 Feb; 306(1):170-80. PubMed ID: 12620809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.
    Osorio JE; Huang CY; Kinney RM; Stinchcomb DT
    Vaccine; 2011 Sep; 29(42):7251-60. PubMed ID: 21777638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis.
    Lai CJ; Monath TP
    Adv Virus Res; 2003; 61():469-509. PubMed ID: 14714441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells.
    Brandler S; Brown N; Ermak TH; Mitchell F; Parsons M; Zhang Z; Lang J; Monath TP; Guirakhoo F
    Am J Trop Med Hyg; 2005 Jan; 72(1):74-81. PubMed ID: 15728870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.
    Guirakhoo F; Arroyo J; Pugachev KV; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Soike K; Ratterree M; Monath TP
    J Virol; 2001 Aug; 75(16):7290-304. PubMed ID: 11462001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys.
    Whitehead SS; Hanley KA; Blaney JE; Gilmore LE; Elkins WR; Murphy BR
    Vaccine; 2003 Oct; 21(27-30):4307-16. PubMed ID: 14505913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response.
    van Der Most RG; Murali-Krishna K; Ahmed R; Strauss JH
    J Virol; 2000 Sep; 74(17):8094-101. PubMed ID: 10933719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.